A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP
Public ClinicalTrials.gov record NCT06920004. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Randomized, Double-Blinded, Double-Dummy Study Evaluating the Efficacy and Safety of Intravenous Empasiprubart Versus Intravenous Immunoglobulin in Adults With Chronic Inflammatory Demyelinating Polyneuropathy
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The main purpose of this study is to compare empasiprubart and IVIg for treating people with CIDP. This study consists of a Part A where participants will either receive empasiprubart and a placebo resembling IVIg, or IVIg and a placebo resembling empasiprubart for 24 weeks (6 months). Following Part A, participants will enter Part B in which all participants will receive empasiprubart for 96 weeks (24 months). More information can be found here: https://clinicaltrials.argenx.com/emvigorate
Study identification
- NCT ID
- NCT06920004
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 218 participants
Conditions and interventions
Conditions
Interventions
- empasiprubart Biological
- IVIg Biological
- empasiprubart-placebo Other
- IVIg-placebo Other
Biological · Other
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 22, 2025 (Actual)
- Primary completion
- Sep 2027 (Estimated)
- Completion
- Sep 2030 (Estimated)
- Last update posted
- Oct 16, 2026
2025 – 2030
United States locations
- U.S. sites
- 16
- U.S. states
- 12
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama | Birmingham | Alabama | 35233 | Recruiting |
| Samir Macwan, M.D., Inc. | Rancho Mirage | California | 922701 | Recruiting |
| Colorado Springs Neurological Associates | Colorado Springs | Colorado | 80907 | Recruiting |
| MedStar Washington Hospital Center | Washington D.C. | District of Columbia | 20010 | Recruiting |
| Homestead Associates in Research Inc | Homestead | Florida | 33033 | Recruiting |
| Visionary Investigators Network | Miami | Florida | 33133 | Recruiting |
| University of South Florida | Tampa | Florida | 33616 | Recruiting |
| Baptist Health Medical Group Neurology | Nicholasville | Kentucky | 40356-6066 | Recruiting |
| Paradigm Health System | Slidell | Louisiana | 70458 | Recruiting |
| Erlanger Health System | Columbia | Maryland | 21044 | Recruiting |
| University of Michigan Hospital | Ann Arbor | Michigan | 48109 | Recruiting |
| University of Cincinnati Health | Cincinnati | Ohio | 45267-2827 | Recruiting |
| Perelman Center for Advanced Medicine | Philadelphia | Pennsylvania | 19104-5127 | Recruiting |
| Jefferson Health Honickman Center | Philadelphia | Pennsylvania | 19107 | Recruiting |
| NeuroCarePlus | Houston | Texas | 77094 | Recruiting |
| National Neuromuscular Research Institute | Irving | Texas | 75063 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 86 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06920004, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 16, 2026 · Synced Oct 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT06920004 live on ClinicalTrials.gov.